Navigation Links
Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
Date:10/12/2009

EAST HANOVER, N.J., Oct. 12 /PRNewswire-FirstCall/ -- Novartis Pharma AG has entered into an agreement for exclusive US and Canadian rights to Fanapt(TM) (iloperidone), a new oral medication that is approved by the US Food and Drug Administration (FDA) for the acute treatment of adults with schizophrenia. Novartis plans to launch Fanapt in the US in early 2010.

As part of the agreement with Vanda Pharmaceuticals Inc., Novartis will have exclusive commercialization rights to the oral formulation of this medicine in the US and Canada as well as exclusive rights to develop and commercialize a long-acting injectable (or "depot") formulation of this medicine for these markets.

Schizophrenia is a severe psychiatric disorder that is estimated to affect more than 2 million adults in the US and nearly 250,000 Canadians. Fanapt belongs to a class of medication for schizophrenia known as atypical antipsychotics.

"Schizophrenia remains one of the most chronic and debilitating of the major psychiatric illnesses, underscoring the need for new treatment options," said Ludwig Hantson, PhD, Head of Pharma North America, CEO, Novartis Pharmaceuticals Corporation. "With the launch of Fanapt in early 2010, we will broaden our presence in psychiatry and build on the heritage of Novartis in offering innovative treatments for devastating psychiatric diseases."

In the 1970s, Novartis pioneered the first atypical antipsychotic medication which was considered a breakthrough for patients with treatment-resistant schizophrenia. Novartis also offers medications for Alzheimer's disease, attention deficit hyperactivity disorder (ADHD), Parkinson's disease and multiple sclerosis.

Vanda completed Phase III clinical trials in 2006 and gained US regulatory approval for this medicine in May 2009.

Terms of the agreement

Novartis will make an upfront payment to Vanda of USD 2
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
2. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
3. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
4. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
6. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
7. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
8. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
9. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
10. Orion Genomics Enters Discovery Collaboration and License Agreement to Advance Personalized Diagnostics
11. Elbit Imaging Ltd. Announces Sale of Plaza Centers Shares
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Sept. 2, 2015 About Duchenne muscular ... disease, which generally affects the male population. It ... The disease is caused due to mutations in ... of production of dystrophin (a protein essential for ... of dystrophin weakens muscle function, causes loss of ...
(Date:9/2/2015)...  Array BioPharma Inc. (Nasdaq: ARRY ) ... Ron Squarer , will present at the Wells ... is welcome to participate in the conference through ... Fargo Securities Healthcare ConferencePresenter: Ron Squarer, Chief Executive ... a.m. Eastern Time Webcast: www.arraybiopharma.com   ...
(Date:9/2/2015)... YORK , Sept. 2, 2015 About ... is a malignant condition characterized by increased production of ... affects B-lymphocytes and then it can spread to other ... at later stages because of the slow buildup of ... the malignancy spreads to the spleen, liver, and lymph ...
Breaking Medicine Technology:Global Duchenne Muscular Dystrophy Drugs Market 2015-2019 2Global Duchenne Muscular Dystrophy Drugs Market 2015-2019 3Global Chronic Lymphocytic Leukemia Therapeutics Market 2015-2019 2Global Chronic Lymphocytic Leukemia Therapeutics Market 2015-2019 3
... Xlumena, Inc., a privately-held provider of innovative technology ... that it has received CE Mark approval for its ... system that enables exchange-free access, tract dilation and delivery ... NAVIX will join the AXIOS Stent and Delivery System ...
... The Chinese Biopharmaceutical Association-USA (CBA) successfully held its 16 ... US.   With the theme of ... the conference drew nearly 500 attendees with ... exhibited at the conference, including Chinese leading biotech parks, ...
Cached Medicine Technology:Xlumena Receives CE Mark for NAVIX™, Second Product to Enter European Market 2Chinese Biopharmaceutical Association Successfully Holds 16th Annual Conference 2Chinese Biopharmaceutical Association Successfully Holds 16th Annual Conference 3
(Date:9/2/2015)... ... September 02, 2015 , ... Telehealth represents a growing trend among ... handle the telehealth services of more than 12 Blues plan clients. The September ... takes a look this growing trend, interviewing executives at Capital Blue Cross, whose telehealth ...
(Date:9/2/2015)... ... September 02, 2015 , ... In “Failure Lab: Weight Loss Surgery was ... August 25th, writer Akela Stanfield detailed her lifelong struggle with obesity that eventually led ... had always seen herself as someone who would lose weight through sheer self-control, the ...
(Date:9/2/2015)... ... September 02, 2015 , ... Splashtop Inc., the ... to its screen mirroring and extending product line -- Splashtop Wired XDisplay ... in local WIFI setting, the new Splashtop Wired XDisplay delivers enhanced performance and ...
(Date:9/2/2015)... ... September 02, 2015 , ... Good health and a good ... Shield of New Jersey (Horizon BCBSNJ) donated $11,000 to the New Jersey Golf Foundation ... foundation at the start of The Barclays, Horizon BCBSNJ challenged PGA TOUR golfer and ...
(Date:9/2/2015)... , ... September 02, 2015 , ... ... combining both naturopathic and allopathic medicine, opens its second location this week at ... features roughly 1000 square feet of lounge space for patients to relax while ...
Breaking Medicine News(10 mins):Health News:AIS Newsletter Focuses on Growing Telehealth Trend Among Blues Plans 2Health News:AIS Newsletter Focuses on Growing Telehealth Trend Among Blues Plans 3Health News:Recent Editorial on Bariatric Surgery Acceptance Illuminates a Typical Journey Towards Weight Loss Surgery, Notes Dr. Michael Feiz 2Health News:Splashtop Launches Wired XDisplay, the Fastest Screen Sharing Solution for Extending and Mirroring Your Computer Screen to Mobile Devices 2Health News:Splashtop Launches Wired XDisplay, the Fastest Screen Sharing Solution for Extending and Mirroring Your Computer Screen to Mobile Devices 3Health News:Horizon BCBSNJ’s Healthy Steps Challenge Raises an Additional $6,000 for the NJ Golf Foundation with Help from PGA TOUR Golfer Morgan Hoffmann 2Health News:Horizon BCBSNJ’s Healthy Steps Challenge Raises an Additional $6,000 for the NJ Golf Foundation with Help from PGA TOUR Golfer Morgan Hoffmann 3Health News:The Hydration Room Opens New Location In Laguna Beach, California 2Health News:The Hydration Room Opens New Location In Laguna Beach, California 3Health News:The Hydration Room Opens New Location In Laguna Beach, California 4
... ABT ),will present at the Citi Investment Research ... C. Freyman, executive vice president,finance and chief financial officer, ... Central time., A live audio webcast of the ... at http://www.abbottinvestor.com . An,archived edition of the presentation ...
... With the economy tight and,sales forces shrinking across ... maintain an effective sales force. Regardless, a company,s ... success going forward. That,success is predicated on establishing ... goals and managing groups in a way,that meets ...
... increase the risk of Alzheimers Disease by as much as ... issue of Obesity Reviews. , But its not just weight ... have an elevated risk of dementia, unlike people who are ... detailed review of 10 international studies published since 1995, covering ...
... staffing company to launch nationally-syndicated television ... ... Access,Nurses announced today a national campaign to change the image of nursing,in ... lives of nurses working on the front lines of modern,healthcare. The show, ...
... May 7 Emageon Inc. (Nasdaq:,EMAG), a leader in ... imaging facilities, will hold its,quarterly conference call to discuss ... at 10:00 AM Eastern Time. The company anticipates,that these ... the NASDAQ,stock market opens on May 12, 2008., ...
... May 7 AMDL, Inc. (Amex: ... in Shenzhen, Jiangxi,and Jilin, China, is a ... its subsidiary Jade Pharmaceutical Inc. (JPI),the Company ... of diagnostic, pharmaceutical, nutritional supplement, and,cosmetic products., ...
Cached Medicine News:Health News:Best Practice Database: Complimentary Excerpt of Three Sales Force Excellence Studies 2Health News:Obesity can increase dementia risk by up to 80 percent 2Health News:Nursing Shortage Spurs Campaign to Change the Image of Nursing in the Media 2Health News:Emageon Inc. to Host First Quarter 2008 Financial Results Conference Call May 12, 2008 2Health News:AMDL Signs Letter of Intent to Purchase a China Based Pharmaceutical Distribution Company 2Health News:AMDL Signs Letter of Intent to Purchase a China Based Pharmaceutical Distribution Company 3
... This double ended instrument was designed to ... up to one year postoperatively. The curved ... surgeon to lift the edge and then ... is used to smooth and reposition the ...
Smaller than the kuglen hook, this manipulator offers excellent grasping or lifting of the nucleus. Blunt finger-like 0.5 mm two-prong tip. Round knurled handle with dull finish. Angled....
This double ended instrument was designed for delineating and lifting the corneal flap of previously performed lamellar refractive surgery cases....
Short, narrow paddle angled 45 degree inserts through the side port stab incision and is ideal for effective manipulation of the lens during anterior chamber phacoemulsification....
Medicine Products: